

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: April 14, 2004 (use as many sheets as necessary)		Application Number	Unassigned
		Filing Date	04/14/2004
		First Named Inventor	Sunghoon KIM
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet 1 of 2	Attorney Docket Number	058333-0118	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
LDL	A1	WO	00/73801	A2	LUDWIG INSTITUTE FOR CANCER RESEARCH	12-07-2000		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
LDL	A2	QUEVILLON, S. et al. "The p43 Component of the Mammalian Multi-synthetase Complex Is Likely to be the Precursor of the Endothelial Monocyte-activating Polypeptide II Cytokine", J.Biol.Chem. (1997), Vol. 272, No. 51, pp. 32573-32579, The American Society for Biochemistry and Molecular Biology, Inc.	
	A3	BEHRENSDORF, H. et al. "The endothelial monocyte-activating polypeptide II (EMAP II) is a substrate for caspase-7" FEBS Lett., (2000), Vol. 466, pp. 143-147, Federation of European Biochemical Societies.	
	A4	KAO, J. et al. "A Peptide Derived from the Amino Terminus of Endothelial-Monocyte-activating Polypeptide II Modulates Mononuclear and Polymorphonuclear Leukocyte Functions, Defines an Apparently Novel Cellular Interaction Site, and Induces an Acute Inflammatory Response", J. Biol. Chem. (1994), Vol. 269, No. 13, pp. 9774-9782, The American Society for Biochemistry and Molecular Biology, Inc.	
	A5	KAO, J. et al. "Endothelial Monocyte-activating Polypeptide II: A Novel Tumor-Derived Polypeptide That Activates Host-Response Mechanisms", J. Biol. Chem. (1992), Vol. 267, No. 28, pp. 20239-20247, The American Society for Biochemistry and Molecular Biology, Inc.	
	A6	KAO, J. et al. "Characterization of a Novel Tumor-derived Cytokine: Endothelial-Monocyte Activating", J. Biol. Chem. (1994), Vol. 269, No. 40, pp. 25106-25119, The American Society for Biochemistry and Molecular Biology, Inc.	
	A7	KNIES, U.E. et al., "Regulation of endothelial monocyte-activating polypeptide II release by apoptosis", Proc. Natl. Acad. Sci. USA (1998), Vol. 95, pp. 12322-12337.	
	A8	SCHWARZ, M.A. et al., "Endothelial-Monocyte Activating Polypeptide II, A Novel Antitumor Cytokine that Suppresses Primary and Metastatic Tumor Growth and Induces Apoptosis in Growing Endothelial Cells", J. Exp. Med. (1999) Vol. 190, No. 3, pp. 341-352, The Rockefeller University Press.	
	A9	TAS, M.P.R. and MURRAY, J.C., "Endothelial-Monocyte-Activating Polypeptide II", Int. J. Biochem. Cell. Biol. (1996), Vol. 28, No. 8, pp. 887-841, 1996 Elsevier Science Ltd.	

Examiner Signature		Date Considered	8-30-04
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: April 14, 2004 (use as many sheets as necessary)		Application Number	Unassigned
		Filing Date	04/14/2004
		First Named Inventor	Sunghoon KIM
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	2	of	2
		Attorney Docket Number	058333-0118

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
CLC	A10	SCHLUESENER, H.J. et al., "Localization of Endothelial-Monocyte-Activating Polypeptide II (EMAP II), a Novel Proinflammatory Cytokine, to Lesions of Experimental Autoimmune Encephalomyelitis, Neuritis, and Uveitis", GLIA (1997), Vol. 20, pp. 365-372, Wiley-Liss, Inc.	
I	A11	BERGER, A.C. et al., "Endothelial Monocyte-Activating Polypeptide II, a Tumor-Derived Cytokine That Plays an Important Role in Inflammation, Apoptosis, and Angiogenesis", J. Immunother. (2000), Vol. 23, No. 5, pp. 519-527, Lippincott, Williams and Wilkins, Inc.	
I	A12	KO, Y.G. et al., "A Cofactor of tRNA Synthetase, p43, Is Secreted to Up-regulate Proinflammatory Genes", J. Biol. Chem. (2001), Vol. 276, No. 25, pp. 23028-23033, The American Society for Biochemistry and Molecular Biology, Inc.	
	A13	PARK, S.G. et al., "Precursor of Pro-apoptotic Cytokine Modulates Aminoacylation Activity of tRNA Synthetase", J. Biol. Chem. (1999), Vol. 274, No. 24, pp. 16673-16676, The American Society for Biochemistry and Molecular Biology, Inc.	

Examiner Signature		Date Considered	8.30.04
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.